The latest Breast Cancer Update 2006 (
http://www.breastcancerupdate.com/bcu2006/2/default.htm) has a huge amount of information in particular (but not exclusively) on HER+ cancers.
While the site is intended to supply information on recent treatment developments to the medical community it is in general quite readable for the non expert.
This is resulting from the verbal format used: informal interviews or comments or discussions. So there no excessive amount of complex biology & the comments are often interesting as they go beyond the the strict scientific presentation of the results of clinical trials. (Several commentators were involved in the running of clinical trials)
There are for instance variations on treatment protocols justified for individual cases or classes of patients by some oncologists (see one example by Dr Kent Osborne on high dose Fulvestrant).
A section called
Controversies in Systemic Therapy of Breast Cancer. Special Edition (
http://www.breastcancerupdate.com/bc...me/default.htm) has the replies of expert clinicians to treatment questions by prime caregivers in 8 individual patient cases. It is interesting in the comments to justify the treatment selections.
There are many audio renditions of the talks (
http://www.breastcancerupdate.com/do.../2/default.asp) as well as some in script.
The audio sessions are conveniently subdivided in sections (called tracks) which may be selected for separate listening.
I wonder if someone would listen to Track 20 of Dr Kathleen Pritchard interview to identify the name of the drug (which she says is similar to Herceptin) but crosses the blood-brain barrier & is a candidate to treat brain tumours.
This track is titled
Incidence of brain metastases in patients receiving trastuzumab.(
http://www.breastcancerupdate.com/do.../default.asp#2)
I was not able to decipher the spelling of that drug she names at the end of Track 20 .
Threaded Mode